1. EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL. (June 2017) Authors: Pettitt, A.R.; Kalakonda, N.; Polydoros, F.; Bickerstaff, M.; Menon, G.; Coupland, S.E.; Oates, M.; Lin, K.; Pocock, C.; Jenkins, S.; Schuh, A.; Wandroo, F.; Rassam, S.; Duncombe, A.S.; Jenner, M.; Cervi, P.; Paneesha, S.; Aldouri, M.; Fox, C.P.; Knechtli, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 88 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA‐NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T‐CELL PROJECT. (June 2017) Authors: Fox, C.P.; Bellei, M.; Manni, M.; Kim, S.J.; Ko, Y.H.; Shustov, A.R.; Cabrera, M.E.; Chiattone, C.S.; Horwitz, S.M.; Spina, M.; Advani, R.H.; Angrilli, F.; De Souza, C.A.; Dlouhy, I.; Fernandez‐Alvarez, R.; Gabús, R.; Hitz, F.; Laszlo, D.; Montoto, S.; Nagler, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET‐GUIDED, RESPONSE‐ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED‐STAGE, HIGH‐TUMOUR‐BURDEN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Pettitt, A.R.; Barrington, S.; Kalakonda, N.; Khan, U.T.; Jackson, R.; Carruthers, S.; Oates, M.; Lin, K.; Ardeshna, K.; Eyre, T.; Fox, C.P.; Kennedy, B.; Linton, K.; Malladi, R.; Menne, T.; Okosun, J.; Paneesha, S.; Rule, S.; Johnston, A.; Trotman, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗